WebCoverage for Epogen or Procrit is contingent on . Medical Necessity Criteria. and Diagnosis-Specific Criteria. In order to continue coverage, members already on these products will … WebOn May 15, 2024, the Food and Drug Administration approved Retacrit (epoetin alfa-epbx, Hospira Inc., a subsidiary of Pfizer Inc.) as a biosimilar to Epogen/Procrit (epoetin alfa, …
HIGHLIGHTS OF PRESCRIBING INFORMATION
WebOct 31, 2013 · The aims of the Aranesp Efficiency Relative to Mircera (AFFIRM) study were primarily to estimate the maintenance dose conversion ratio (DCR) of PEG-Epo to DA in a population of European hemodialysis patients switched from DA to PEG-Epo and with comparable mean hemoglobin (Hb) in the pre- and post-switch periods, and secondarily … WebEpoetin alfa and darbepoetin alfa are Erythropoiesis-Stimulating Agents (ESAs), approved for the treatment of anemia (low red blood cells) resulting from chronic kidney disease, chemotherapy,... paullo asst
Mircera (methoxy polyethylene glycol / epoetin beta) …
WebAdminister Mircera IV once every 4 weeks to pediatric persons (ages 5 to 17 years) whose hemoglobin level has been stabilized by treatment with an ESA. Administer Mircera as an IV injection at the dose (in micrograms) based on the total weekly ESA dose at the time of conversion (see below): Source: Hoffman-La Roche, 2024 WebMar 2, 2007 · This 2 arm study will compare the effect on hemoglobin response of Mircera and epoetin beta, in patients with chronic renal anemia who are on dialysis. Eligible patients will be randomized to receive either Mircera (0.4 micrograms/kg i.v. every 2 weeks) or epoetin beta (3 times weekly, according to approved labelling). WebErythropoiesis stimulating agent (ESA)-naive patient not on dialysis 1.2 mcg/kg SC inj once mthly. Alternatively, 0.6 mcg/kg IV or SC inj once every 2 wk. ESA-naive patient on … paul lizotte md